Large gap with delayed quotes
|
Last quote
02/28/2026
-
02:00:00
|
Bid
02/27/2026 -
21:59:59
|
Bid Volume |
Ask
02/27/2026 -
21:59:59
|
Ask Volume |
|---|---|---|---|---|
|
69.53
+0.31
(
+0.45% )
|
69.53
|
12,000 |
69.54
|
500 |
Analysis date: 24.02.2026
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 26.12.2025.
Interest
Strong
Strong
Three stars since 20.02.2026.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 26.12.2025 at a price of 68.87.
Evaluation
Undervalued
Undervalued
Based on its growth potential and our own criteria, we believe the share price is currently moderately undervalued.
MT Tech Trend
Negative
Negative
The dividend-adjusted forty day technical trend is negative since 20.02.2026.
4wk Rel Perf
2.02%
2.02%
The four-week dividend-adjusted overperformance versus SP500 is 2.02%.
Sensibility
High
High
The stock has been on the high-sensitivity level since 13.05.2025.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -1.07%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 4.30%.
Mkt Cap in $bn
8.30
8.30
With a market capitalization >$8bn, HALOZYME THERAPEUTICS is considered a large-cap stock.
G/PE Ratio
3.66
3.66
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
6.23
6.23
The estimated PE is for the year 2028.
LT Growth
22.78%
22.78%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
4
4
Over the last seven weeks, an average of 4 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
17
17
For 1% of index variation, the stock varies on average by 0.17%.
Correlation
0.08
0.08
Stock movements are totally independent of index variations.
Value at Risk
16.89
16.89
The value at risk is estimated at USD 16.89. The risk is therefore 24.01%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
28.07.2010
28.07.2010